https://doi.org/10.18502/ijrm.v21i9.14402
statistics
- 94 Abstract Views
- 57 PDF Views
- 0 HTML Views
authors
-
Roya Kabodmehri
Roya Kabodmehri
Reproductive Health Research Center, Department of Obstetrics and Gynecology, Al-zahra Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
-
Nasrin Ghanami Gashti
Nasrin Ghanami Gashti
Reproductive Health Research Center, Department of Obstetrics and Gynecology, Al-zahra Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
-
Azadeh Raoufi
Azadeh Raoufi
Mehr Fertility Research Center, Guilan University of Medical Sciences, Rasht, Iran.
-
Marzieh Mehrafza
Marzieh Mehrafza
Mehr Fertility Research Center, Guilan University of Medical Sciences, Rasht, Iran.
-
Zahra Nikpouri
Zahra Nikpouri
Mehr Fertility Research Center, Guilan University of Medical Sciences, Rasht, Iran.
-
Elmira Hosseinzadeh
Elmira Hosseinzadeh
Mehr Fertility Research Center, Guilan University of Medical Sciences, Rasht, Iran.
-
Ahmad Hosseini
Ahmad Hosseini
Mehr Fertility Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Published Date
- Oct 26, 2023
Pregnancy outcome in long- versus short-acting gonadotropin-releasing hormone agonist cycles in participants with normal ovarian reserve: An RCT
Abstract
Background: There is no agreement on which of the 2 gonadotropin-releasing hormone (GnRH) agonist protocols are the most efficient, neither there is any consensus on which one yields a better clinical pregnancy percentage.
Objective: The present study aims to compare the effectiveness of reduced dosages of long- and short-acting GnRH agonists on pregnancy outcomes.
Materials and Methods: In this randomized controlled clinical trial, 400 women were randomly assigned to 2 groups (n = 200/group): the reduced dosage of long-acting GnRH agonist group (group 1, 1.25 mg Decapeptyl) and the short-acting GnRH agonist group (group 2, 0.5 mg/day Buserelin Acetate). The study was conducted at Mehr Medical Institute, Rasht, Iran between July 2019 and July 2020. Biochemical and clinical pregnancy were compared between groups.
Results: No significant differences were observed in the endometrial lining, the total number of retrieved and metaphase-II oocytes, progesterone, and serum estradiol levels on human chorionic gonadotropin day, fertilization rate, and top-quality embryos between the groups. The duration of induction (10.8 ± 1.7 vs. 10 ± 2.1, p < 0.001) and the total dosage of gonadotropins (2939.4 ± 945.9 vs. 2441 ± 1247.1, p < 0.001) were significantly greater in group 2 than in group 1. No significant differences were observed between the 2 groups in terms of implantation rate, chemical pregnancy rate, and clinical pregnancy rate. A higher percentage of ovarian hyperstimulation syndrome was observed in group 2 (p = 0.005).
Conclusion: Due to a lower percentage of ovarian hyperstimulation syndrome in group 1 and similar assisted reproductive technology outcomes in both groups, the long protocol was found to be superior to the short protocol.
Key words: Gonadotropin-releasing hormone, In vitro fertilization, Pregnancy outcome, Ovarian hyperstimulation syndrome.
References
2. Al‐Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2016; 4: CD001750.
3. Kim H, Han SJ, Hong YS, Kim SW, Ku S-Y, Suh CS, et al. Optimal oocyte number in controlled ovarian stimulation with gonadotropin-releasing hormone agonist/antagonist and day 3 fresh embryo transfer. Reprod Sci 2021; 28: 2861-2868.
4. Ying Y, Yang T, Zhang H, Liu Ch, Zhao J. Prolonged pituitary down-regulation with full-dose of gonadotropin-releasing hormone agonist in different menstrual cycles: A retrospective cohort study. Peer J 2019; 7: e6837.
5. Haydardedeoğlu B, Kılıçdağ EB. A novel approach using a minimal number of injections during the IVF/ICSI cycle: Luteal half-dose depot GnRH agonist following corifollitropin alfa versus the corifollitropin alfa with a GnRH-antagonist cycle. J Turk Ger Gynecol Assoc 2016; 17: 155-158.
6. Chen X, Feng Sh-X, Guo P-P, He Y-X, Liu Y-D, Ye D-Sh, et al. Does lower dose of long-acting triptorelin maintain pituitary suppression and produce good live birth rate in long down-regulation protocol for in-vitro fertilization? J Huazhong Univ Sci Technolog Med Sci 2016; 36: 215-220.
7. Umemmuo MU, Efetie ER, Agboghoroma CO, Momoh JA, Ikechebelu JI. Comparison of clinical efficacy of long-versus short-acting gonadotrophin-releasing hormone agonists for pituitary down regulation in in vitro fertilisation cycles. Niger Postgrad Med J 2020; 27: 171-176.
8. Liao C, Huang R, Scherer RW, Liang X-Y. Prognostic factors associated with clinical pregnancy in in vitro fertilization using pituitary down-regulation with depot and daily low-dose luteal phase gonadotropin releasing hormone agonists: A single center's experience. J Hum Reprod Sci 2015; 8: 30-36.
9. Xu B, Geerts D, Hu S, Yue J, Li Z, Zhu G, et al. The depot GnRH agonist protocol improves the live birth rate per fresh embryo transfer cycle, but not the cumulative live birth rate in normal responders: A randomized controlled trial and molecular mechanism study. Hum Reprod 2020; 35: 1306-1318.
10. Farquhar C, Marjoribanks J. Assisted reproductive technology: An overview of Cochrane reviews. Cochrane Database Syst Rev 2018; 8: CD010537.
11. Schoolcraft WB, Gardner DK, Lane M, Schlenker T, Hamilton F, Meldrum DR. Blastocyst culture and transfer: Analysis of results and parameters affecting outcome in two in vitro fertilization programs. Fertil Steril 1999; 72: 604-609.
12. Mao G-H, Feng Z, He Y, Huang Y-R. Comparisons of the effects of long-acting and short-acting GnRH agonists on embryo quality, endometrial thickness and pregnancy rate in human in vitro fertilization. Arch Med Sci 2014; 10: 161-166.
13. Yovich JL. Monitoring the stimulated IVF cycle. In: Kovacs GR, Rutherford AJ, Gardner DK. How to prepare the egg and embryo to maximise IVF success. Cambridge: Cambridge University Press; 2019. 94-120.
14. Blumenfeld Z. What is the best regimen for ovarian stimulation of poor responders in ART/IVF? Front Endocrinol 2020; 11: 192.
15. Chen Y, Zhao J, Zhang H. Comparative effectiveness of three ovarian hyperstimulation protocol in in vitro fertilization (IVF) cycles for women with polycystic ovary syndrome. Med Sci Monit 2018; 24: 9424-9428.
16. Huang M-C, Tzeng S-L, Lee C-I, Chen H-H, Huang C-C, Lee T-H, et al. GnRH agonist long protocol versus GnRH antagonist protocol for various aged patients with diminished ovarian reserve: A retrospective study. PLoS One 2018; 13: e0207081.
17. Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, et al. GnRH antagonist versus long agonist protocols in IVF: A systematic review and meta-analysis accounting for patient type. Hum Reprod Update 2017; 23: 560-579.
18. Wu L, Ren X-L, Chen W, Huang B, Zhou Y-F, Jin L. Influence of different gonadotropin-releasing hormone agonist administration methods on pregnancy outcomes of patients undergoing in-vitro fertilization-embryo transfer. Curr Med Sci 2019; 39: 437-441.
19. Gao J, Xu YW, Miao BY, Zhou CQ. Self‐control study on reduced‐dose depot versus daily administration of gonadotrophin‐releasing hormone agonists for pituitary desensitization in in vitro fertilization cycles. J Obstet Gynaecol Res 2014; 40: 1901-1906.
20. Duan L, Bao S, Li K, Teng X, Hong L, Zhao X. Comparing the long‐acting and short‐acting forms of gonadotropin‐releasing hormone agonists in the long protocol of IVF/ICSI cycles: A retrospective study. J Obstet Gynaecol Res 2017; 43: 1037-1042.